Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while mitigating off-target effects in normal tissues, the concept of prodrug-based bispecific antibodies has...
Saved in:
| Main Authors: | Zhijuan Ai, Bing Wang, Yunlong Song, Panpan Cheng, Xinlin Liu, Peng Sun |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523693/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy
by: Daimei Miura, et al.
Published: (2025-05-01) -
Producing and prospects for the use of bispecific antibodies for the treatment of cancer
by: S. E. Sedykh, et al.
Published: (2019-01-01) -
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01) -
Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity
by: Rikuto Nakamura, et al.
Published: (2025-06-01) -
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)